This study aims to explore the potential of adapting prostasin antitumor action targeting the matriptase in B-cell lymphoma to an autologous cell–cell interaction, akin to the mature technology of chimeric antigen receptor T cell (CAR-T) therapy [44,45]. This evidence concerns the gene ST14 and B-cell non-Hodgkin lymphoma.